DNA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DN

Mkt Cap

$692.1M

Volume

3.36M

Next Earnings

November 5th

Loading chart

DN

DNAGinkgo Bioworks Holdings, Inc.

DNA

Pay with—

Available Balance0.00

DN

Mkt Cap

$691.6M

Volume

3.36M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader MarketGinkgo Bioworks Holdings (DNA) declined 1.96% to $11.53, underperforming the S&P 500's 1.11% loss on October 14, 2026. Despite a strong 68.24% monthly gain, the company faces headwinds with expected EPS of -$0.58 and revenue projected to decline 47.22% quarter-over-quarter. Full-year estimates show -$3.2 EPS and 51.69% revenue decline. The stock holds a Zacks Rank #3 (Hold) rating with unchanged consensus estimates over the past 30 days.Zacks Investment Research · Oct 14, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to KnowGinkgo Bioworks (DNA) declined 7.57% in recent trading, significantly underperforming the broader market. The stock has gained 78.82% over the past month but faces headwinds with projected earnings of -$0.58 per share and a 47.22% revenue decline expected. The company holds a Zacks Rank of #3 (Hold), with its industry ranking in the bottom 28% of all sectors.Zacks Investment Research · Oct 7, 2026

AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private SectorsArtificial intelligence is accelerating vaccine adjuvant discovery and optimization, with over $140M in disclosed funding signaling a structural market shift. Major investments include Pfizer and NVIDIA's $80M joint venture into CytoReason and Ginkgo Bioworks' $31M contract with SaponiQx. AI tools are addressing key bottlenecks in antigen-adjuvant optimization and immune response prediction, supported by government initiatives globally. However, regulatory fragmentation, infrastructure gaps, and a shortage of AI-immunology talent remain challenges.GlobeNewswire Inc. · Sep 24, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to KnowGinkgo Bioworks (DNA) declined 8.43% in trading, significantly underperforming the broader market. The stock has gained 24.27% over the past month but faces headwinds with expected earnings of -$0.58 per share and projected revenue decline of 47.22% year-over-year. The company holds a Zacks Rank #3 (Hold) rating with stagnant EPS projections over the past 30 days.Zacks Investment Research · Sep 23, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key FactsGinkgo Bioworks (DNA) closed at $7.06, up 1% while the broader market declined. The stock has gained 7.04% over the past month, outperforming the Medical sector. However, analysts expect significant revenue decline of 47.22% in the upcoming quarter and 51.69% for the full year, with continued losses. The company holds a Zacks Rank of #3 (Hold), and its industry ranks in the bottom 33% of sectors.Zacks Investment Research · Sep 16, 2026

Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors ThinkPalantir and Ginkgo Bioworks are positioned on opposite sides of an emerging biosecurity debate. Palantir represents the intelligence layer for threat identification, while Ginkgo represents the biological infrastructure layer for faster biological responses. The article explores whether future value will come from identifying threats first or building faster biological response capabilities.The Motley Fool · Jun 28, 2026

The $59B Quiet Shift Reshaping How Patients Access CareThe point-of-care diagnostics market has reached $58.76 billion globally in 2026, growing at nearly 10% annually, with projections to reach $114.65 billion by 2035. Five companies are leading this structural shift toward decentralized, consumer-facing healthcare: VentriPoint Diagnostics is expanding globally with AI-powered cardiac imaging; Hims & Hers partnered with Novo Nordisk to offer affordable GLP-1 medications including Wegovy; MannKind is presenting clinical data on Afrezza inhaled insulin; and Ginkgo Bioworks launched Cloud Lab for remote access to autonomous lab infrastructure.Benzinga · May 12, 2026

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventProQR Therapeutics announced pipeline expansion with multiple clinical programs advancing toward the clinic. The company's lead program AX-0810 is on track to report target engagement data in H1 2026, with biliary atresia selected as the initial Phase 2 indication. Additional programs AX-0811, AX-0422, and AX-2911 are progressing with anticipated CTA filings and clinical data readouts expected through 2027. ProQR expects to deliver multiple clinical data readouts within its current cash runway extending into mid-2027.GlobeNewswire Inc. · Apr 8, 2026

A-Alpha Bio Appoints Troy Lionberger as New Chief Business Officer to Drive Next Phase of GrowthA-Alpha Bio, a biotechnology company using synthetic biology and machine learning, has hired Troy Lionberger as Chief Business Officer to lead business development and expand partnerships across biopharma and adjacent sectors.GlobeNewswire Inc. · Sep 23, 2025

Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsightThe microbial fermentation technology market is experiencing significant growth, driven by the increasing incidence of chronic diseases and the growing demand for cutting-edge treatments. North America is expected to dominate the market during the forecast period.GlobeNewswire Inc. · Mar 3, 2025

to start trading

DN

DNAGinkgo Bioworks Holdings, Inc.

DNA

Pay with—

Available Balance0.00

Your PositionYou don't own any DNA yet.

Related Tickers

Earnings